CA9 and renal cell carcinoma: It has been reported that vaccination with CA-IX-derived peptides is an effective immunotherapy for renal cell carcinoma patients (25), and that the addition of bevacizumab, a humanized anti-VEGF monoclonal antibody, to conventional therapy for patients with cervical cancer improves survival rates (26).